Melbourne, Australia, 8 April 2020: The merger of Sienna Cancer Diagnostics Ltd (“Sienna”, ASX:SDX)and BARD1 Life Sciences Limited (“BARD1”, ASX:BD1) will create a well-resourced, Australian-basedcancer diagnostics company with a global presence.
For more information, please download the attached PDF
Download this document
